NEW YORK--(BUSINESS WIRE)--Brookline Capital Markets, a division of Arcadia Securities, LLC, announced today two senior additions to its growing life sciences equity research team: Sally A. Yanchus and Leah Rush Cann.
Following the addition of Leah Rush Cann and Sally A. Yanchus, William B. Buchanan, Jr., a Brookline Managing Partner, said, “the additions of Leah and Sally to our equity research team further demonstrates Brookline’s continued commitment to delivering a unique and differentiated life sciences investment research offering to our growing client base,” adding that “we could not be more pleased with the growth of our public capital markets business and the continued success of our market-leading private capital markets franchise.”
Sally A. Yanchus
Ms. Yanchus is a highly experienced and respected research analyst, having worked for many years on both the buyside and sellside. She has covered the medical technology, diagnostics, global pharmaceuticals, biotechnology, generic pharmaceuticals, and healthcare services sectors. Prior to joining Brookline, Ms. Yanchus was a Global Healthcare Analyst at Tradewinds Global Investors, a division of Nuveen Investments, for approximately 10 years. Ms. Yanchus graduated from Wellesley College with a B.A. in Economics and Statistics and a concentration in Biotechnology, and she received her M.B.A. in Finance and Accounting from Columbia Business School.
Leah Rush Cann
Mrs. Cann has had a long and distinguished career as a buyside analyst, sellside analyst and portfolio manager, and biotechnology consultant. Prior to joining Brookline, she was a Senior Biotechnology Analyst at Oppenheimer & Co. In addition, Leah Rush Cann also serves or has served on a number of boards in the healthcare industry. She earned her B.A. in Art History and Chemistry, as well as her M.B.A., from Stetson University. She also pursued post-baccalaureate studies at The College of William & Mary and post-graduate studies at Columbia University.
With the addition of Ms. Yanchus and Mrs. Cann to the Brookline team, Brookline now has three publishing life sciences analysts, as well as a strategic research partnership agreement with Edison Investment Research. In total, the firm now covers more than 40 life sciences companies.
Brookline Capital Markets, a division of Arcadia Securities, LLC, is a leading healthcare-focused investment banking boutique based in New York City. Brookline provides a comprehensive suite of capital markets and strategic advisory services to cutting-edge public and private life sciences, medical technology, and diagnostics companies, as well as to Special Purpose Acquisition Companies (“SPACs”) and other emerging growth enterprises.
600 Lexington Avenue, 33rd Floor | New York, New York 10022 | Tel: 646-248-5085 | www.brooklinecapmkts.com
Securities offered through Arcadia Securities, LLC
A Registered Broker/Dealer | Member: FINRA/SIPC